AMLX

3.65

3.99% 0.14

Handel nachbörslich: 3.65

Amylyx Pharmaceuticals Inc (AMLX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$3.51

Offen:

$3.51

24-Stunden-Volumen:

1.39M

Relative Volume:

1.28

Marktkapitalisierung:

$312.77M

Einnahmen:

$380.79M

Nettoeinkommen (Verlust:

$49.27M

KGV:

5.2143

EPS:

0.7

Netto-Cashflow:

$10.68M

1W Leistung:

+1.39%

1M Leistung:

-3.44%

6M Leistung:

+77.18%

1J Leistung:

-77.19%

1-Tages-Spanne:

$3.47

$3.75

1-Wochen-Bereich:

$3.2109

$3.75

52-Wochen-Spanne:

$1.575

$19.95

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Firmenname

Amylyx Pharmaceuticals Inc

Sektor

Healthcare (1173)

Branche

Biotechnology (678)

Telefon

617-683-0917

Adresse

43 THORNDIKE STREET, CAMBRIDGE

Mitarbeiter

384

Twitter

Nächster Verdiensttermin

2024-08-08

Neueste SEC-Einreichungen

AMLX's Discussions on Twitter

Vergleichen Sie AMLX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AMLX Amylyx Pharmaceuticals Inc	3.65	312.77M	380.79M	49.27M	10.68M	0.70
VRTX Vertex Pharmaceuticals Inc	461.68	118.90B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	672.98	73.95B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	655.13	39.81B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	271.31	34.99B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	123.77	29.67B	3.30B	-501.07M	1.03B	-2.1146

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-18	Hochstufung	Robert W. Baird	Neutral → Outperform
2024-10-23	Hochstufung	BofA Securities	Neutral → Buy
2024-03-18	Herabstufung	Mizuho	Buy → Neutral
2024-03-11	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-03-11	Herabstufung	Robert W. Baird	Outperform → Neutral
2024-03-08	Herabstufung	Evercore ISI	Outperform → In-line
2024-03-08	Herabstufung	Goldman	Buy → Neutral
2024-01-03	Eingeleitet	Robert W. Baird	Outperform
2023-12-12	Eingeleitet	Deutsche Bank	Buy
2023-07-24	Hochstufung	Goldman	Neutral → Buy
2023-03-31	Eingeleitet	Mizuho	Buy
2023-01-05	Eingeleitet	BofA Securities	Buy
2022-05-25	Eingeleitet	Citigroup	Buy
2022-04-01	Herabstufung	Goldman	Buy → Neutral

Alle ansehen

Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten

Feb 01, 2025

FY2025 Earnings Forecast for AMLX Issued By Leerink Partnrs - MarketBeat

Feb 01, 2025

Jan 31, 2025

Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Jan 31, 2025

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Update - MarketBeat

Jan 31, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - Markets Insider

Jan 31, 2025

JPMorgan Chase & Co. Purchases 83,048 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat

Jan 31, 2025

Jan 30, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - Markets Insider

Jan 30, 2025

2025-01-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation | NDAQ:AMLX | Press Release - Stockhouse Publishing

Jan 30, 2025

Jan 24, 2025

FDA lifts clinical hold on Amylyx ALS drug study - MSN

Jan 24, 2025

FDA clears Amylyx to resume ALS drug trial in North America - MSN

Jan 24, 2025

Fierce Biotech Names Amylyx Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2020 - Marketscreener.com

Jan 24, 2025

Jan 23, 2025

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis - Business Wire

Jan 21, 2025

Jan 15, 2025

Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $7.33 - MarketBeat

Jan 15, 2025

Jan 13, 2025